Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synthetic MR ABXSAT:SYNT +1.32%63 Quick Ratio is 3.04 as of Mar. 2026, which is 27% below its 10-year median of 4.15. GuruFocus rates XSAT:SYNT with a GF Score™ of 63/100 and a GF Value™ of kr4.59 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 680 Healthcare Providers & Services companies, Synthetic MR AB ranks better than 79.41% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Synthetic MR AB's quick ratio for the quarter that ended in Mar. 2026 was 3.04.
Synthetic MR AB has a quick ratio of 3.04. It generally indicates good short-term financial strength.
The historical rank and industry rank for Synthetic MR AB's Quick Ratio or its related term are showing as below:
XSAT:SYNT'
s Quick Ratio Range Over the Past 10 Years
Min: 2.07 Med: 4.15 Max: 6.38
Current: 3.04
During the past 13 years, Synthetic MR AB's highest Quick Ratio was 6.38. The lowest was 2.07. And the median was 4.15.
XSAT:SYNT's Quick Ratio is ranked better than 79.41% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 1.32
vs XSAT:SYNT: 3.04
Synthetic MR AB (XSAT:SYNT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Synthetic MR AB Quick Ratio Related Terms
Synthetic MR AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Synthetic MR AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:SYNT vs VEEV, BTSG, TEM: Quick Ratio Comparison
For the Health Information Services subindustry, Synthetic MR AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB Quick Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Synthetic MR AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synthetic MR AB (XSAT:SYNT) has a Quick Ratio of 3.04 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Synthetic MR AB and its competitors. This is 27% below median its historical median of 4.15. Over the past decade, Synthetic MR AB's Quick Ratio has ranged from 2.07 to 6.38. According to the industry distribution chart, Synthetic MR AB ranks #140 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 20.6%.
Is Synthetic MR AB's Quick Ratio too high?
Synthetic MR AB's current Quick Ratio of 3.04 is 27% below median its 10-year median of 4.15. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 6.38. The Healthcare Providers & Services industry median Quick Ratio is 1.32. Synthetic MR AB's value of 3.04 is 130.3% above this industry median. Based on the distribution chart, Synthetic MR AB ranks #140 out of 680 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Synthetic MR AB has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's Quick Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Synthetic MR AB ranks #140 out of 680 companies for Quick Ratio. This places Synthetic MR AB in the top 21% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.32. Synthetic MR AB's value of 3.04 is 130.3% above this benchmark. Historically, Synthetic MR AB's own Quick Ratio has ranged from 2.07 to 6.38 over the past decade. While the company's 10-year median is 4.15 vs. the industry median of 1.32, Synthetic MR AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Healthcare Providers & Services company?
The median Quick Ratio among Healthcare Providers & Services companies is 1.32, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synthetic MR AB's current Quick Ratio of 3.04 is 130.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Synthetic MR AB and its competitors. For the Healthcare Providers & Services industry, the median Quick Ratio is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synthetic MR AB's current Quick Ratio is 3.04, which is 27% below median its own 10-year median of 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Based on GuruFocus' analysis, Synthetic MR AB (XSAT:SYNT) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.59, compared to a current price of kr0.62 — trading 86.6% below its estimated fair value. The current Quick Ratio is 3.04, which is 27% below median its 10-year median of 4.15 and 130.3% above the Healthcare Providers & Services industry median of 1.32. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Synthetic MR AB (XSAT:SYNT), the current Quick Ratio is 3.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (XSAT:SYNT) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of kr0.62 is trading 86.6% below its estimated GF Value™ of kr4.59.
GuruFocus considers Synthetic MR AB to be Possible Value Trap.
Key valuation signals for XSAT:SYNT:
Quick Ratio: 3.04 (27% below median its 10-year median of 4.15)
GF Value™: kr4.59 vs. price of kr0.62 (86.6% below fair value)
Industry Position: 130.3% above the Healthcare Providers & Services median (#140 of 680)
No single metric tells the full story. See the XSAT:SYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for XSAT:SYNT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:SYNT has been successfully added to your 
